BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 22322670)

  • 1. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
    Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
    Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
    Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
    Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.
    Sanders ME; Schuyler PA; Dupont WD; Page DL
    Cancer; 2005 Jun; 103(12):2481-4. PubMed ID: 15884091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
    Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
    Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
    Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
    Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
    Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
    J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
    Li CI; Malone KE; Saltzman BS; Daling JR
    Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma.
    Imamura H; Haga S; Shimizu T; Watanabe O; Kajiwara T; Aiba M
    Br J Cancer; 1999 Jan; 79(1):172-8. PubMed ID: 10408711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in reconstruction rates after mastectomy for ductal carcinoma in situ (DCIS): patterns of care and factors associated with the use of breast reconstruction for DCIS compared with invasive cancer.
    Kruper L; Xu X; Henderson K; Bernstein L
    Ann Surg Oncol; 2011 Oct; 18(11):3210-9. PubMed ID: 21863363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
    Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
    Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of chromosomal alterations in breast ductal carcinoma in situ.
    Hwang ES; DeVries S; Chew KL; Moore DH; Kerlikowske K; Thor A; Ljung BM; Waldman FM
    Clin Cancer Res; 2004 Aug; 10(15):5160-7. PubMed ID: 15297420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
    Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.